# Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

> **NCT03054363** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Colorado, Denver** · enrollment: 42 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tucatinib in Combination with Palbociclib and Letrozole
- **DRUG:** Tucatinib in Combination with Palbociclib and Letrozole

## Key facts

- **NCT ID:** NCT03054363
- **Lead sponsor:** University of Colorado, Denver
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-27
- **Primary completion:** 2023-01-17
- **Final completion:** 2023-02-07
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-11-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03054363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03054363, "Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03054363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*